Synthis, LLC
- | Biotech or pharma, therapeutic R&D
Synthis is pioneering a novel (non-cytotoxic) ADC based approach to treating oncology and fibrosis. As the only ADC in the TGFβ space, SYN303 blocks lung fibrosis and inflammation in vivo. We are raising $30M Series A for clinical development of SYN303 and fibrosis platform expansion.
Address
New YorkNY
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}